Latest Cancer immunotherapy Stories
Novel methodology leverages somatic hypermutation to rapidly generate humanized therapeutic antibodies with >97% human content SAN DIEGO, April 3, 2014 /PRNewswire/ -- AnaptysBio,
Morgan Stanley's Head of Global Biotech Investment Banking Joins Leading Cancer Immunotherapy Startup SEATTLE, March 31, 2014 /PRNewswire/ -- Juno Therapeutics, a biotechnology company
SANTA MONICA, Calif., March 31, 2014 /PRNewswire/ -- Kite Pharma, Inc.
BETHESDA, Md., March 27, 2014 /PRNewswire/ -- Northwest Biotherapeutics, Inc.
-- Collaboration Focused on Cancer Immunotherapies for Pets -- KANSAS CITY, Kan., and PRINCETON, N.J., March 19, 2014 /PRNewswire/ -- Aratana
SEATTLE and SOUTH SAN FRANCISCO, Cali., March 18, 2014 /PRNewswire/ -- Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer
HOUSTON, March 17, 2014 /PRNewswire-USNewswire/ -- The University of Texas MD Anderson Cancer Center and MedImmune, the global biologics research and development arm of AstraZeneca, will collaborate
SAN DIEGO, March 13, 2014 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced a strategic immuno-oncology collaboration
A Ludwig Cancer Research study suggests that the clinical efficacy of checkpoint blockade, a powerful new strategy to harness the immune response to treat cancers, might be dramatically improved if combined with oncolytic virotherapy, an investigational intervention that employs viruses to destroy tumors.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.